Company
Tangen Biosciences
Also known as TANGEN BIOSCIENCES, INC.
- Business model
- B2B
- Headquarters
- Branford, Connecticut, United States
- Founded
- 2013
- Legal name
- TANGEN BIOSCIENCES, INC.
Record updated 28 September 2026
About
Tangen Biosciences, Inc. was founded in 2013 and is located in Branford, Connecticut. The company developed the TangenDx™ platform for fast and accurate detection of targeted DNAs and RNAs directly from specimens by using rotary rapid isothermal nucleic acid detection. The Tangen system consists of the TangenDx™ disc and the GeneSpark™ instrument, an automated amplification device. The TangenDx™ platform, which does not require laboratory facilities, is expected to deliver faster, simpler, more sensitive detection at a lower cost than other commercial technologies. Current tests in development include COVID-19, Candida auris, sepsis causing bacterial panel, antibiotic resistance genes, and a fungal blood panel. The system can process samples from whole blood, sputum, skin swabs, nasopharyngeal swabs, etc. The TangenDx FluA/B, RSV, and SARS-CoV-2 Panel assay planned to be released by the upcoming fall season.
Funding snapshot
- Total raised
- $20.4MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $465K2023-05-26
Funding rounds
- Round, 2023
- $465K2023-05-26, SEC form D sold, 9 investors
- Round, 2020
- $11.2M2020-06-19, SEC form D sold, 39 investors
- Round, 2019
- $6.7M2019-03-14, SEC form D sold, 29 investors
- Round, 2016
- 2016-11-02
- Round, 2015
- $2M2015-12-14, SEC form D sold, 8 investors
Products
- Hardware
- TangenDx platform